ClinConnect ClinConnect Logo
Search / Trial NCT03047096

Intra-Articular, Single-shot Injection of Hyaluronic Acid and Corticosteroids in Knee Osteoarthritis

Launched by ZHONGDA HOSPITAL · Feb 7, 2017

Trial Information

Current as of June 18, 2025

Unknown status

Keywords

ClinConnect Summary

Intra-articular injection of hyaluronic acid (HA) or corticosteroids (CS) has been widely used with debate on its efficacy in osteoarthritis (OA). The aim of present study is to to investigate whether the combined injection of HA and CS is superior than HA alone in the treatment of knee OA.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • According to radiographic findings, patients who are suffering from knee OA for over 3 months have to be stage II-IV according to the Kellgren-Lawrence (KL) grade by a senior radiologist. The diagnosis of symptomatic knee OA is based on American Rheumatism Association classification criteria for knee osteoarthritis.
  • Exclusion Criteria:
  • Exclusion criteria are the diagnosis of rheumatoid arthritis or other inflammatory OA, presence of trauma or pain-causing diseases, treatment with oral medications in recent 3 days, physiotherapy and intra-articular injection of HA or CS in the past 6 months. Participants who are allergic to any of the medications used in this study or diagnosed with current systemic infection are also excluded.

About Zhongda Hospital

Zhongda Hospital, a leading medical institution affiliated with Southeast University in Nanjing, China, is dedicated to advancing healthcare through innovative research and clinical trials. With a robust focus on patient-centered care, the hospital combines cutting-edge facilities with a multidisciplinary team of experts to conduct a wide range of clinical studies. Zhongda Hospital is committed to enhancing medical knowledge and improving treatment outcomes across various specialties, fostering collaboration between researchers and healthcare professionals to ensure the highest standards of scientific rigor and ethical practice in all its clinical endeavors.

Locations

Nanjing, Jiangsu, China

Patients applied

0 patients applied

Trial Officials

Shan-zheng Wang, MD

Principal Investigator

Zhongda Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials